Correlation Between Medigen Biotechnology and Golden Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Medigen Biotechnology and Golden Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Biotechnology and Golden Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Medigen Biotechnology and Golden Biotechnology, you can compare the effects of market volatilities on Medigen Biotechnology and Golden Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Biotechnology with a short position of Golden Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Biotechnology and Golden Biotechnology.

Diversification Opportunities for Medigen Biotechnology and Golden Biotechnology

0.7
  Correlation Coefficient

Poor diversification

The 3 months correlation between Medigen and Golden is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Biotechnology and Golden Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Golden Biotechnology and Medigen Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Biotechnology are associated (or correlated) with Golden Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Golden Biotechnology has no effect on the direction of Medigen Biotechnology i.e., Medigen Biotechnology and Golden Biotechnology go up and down completely randomly.

Pair Corralation between Medigen Biotechnology and Golden Biotechnology

Assuming the 90 days trading horizon Medigen Biotechnology is expected to generate 0.94 times more return on investment than Golden Biotechnology. However, Medigen Biotechnology is 1.06 times less risky than Golden Biotechnology. It trades about -0.17 of its potential returns per unit of risk. Golden Biotechnology is currently generating about -0.29 per unit of risk. If you would invest  3,435  in Medigen Biotechnology on September 20, 2024 and sell it today you would lose (235.00) from holding Medigen Biotechnology or give up 6.84% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Medigen Biotechnology  vs.  Golden Biotechnology

 Performance 
       Timeline  
Medigen Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
Golden Biotechnology 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Golden Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Medigen Biotechnology and Golden Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Medigen Biotechnology and Golden Biotechnology

The main advantage of trading using opposite Medigen Biotechnology and Golden Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Biotechnology position performs unexpectedly, Golden Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Golden Biotechnology will offset losses from the drop in Golden Biotechnology's long position.
The idea behind Medigen Biotechnology and Golden Biotechnology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Money Managers
Screen money managers from public funds and ETFs managed around the world
Global Correlations
Find global opportunities by holding instruments from different markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance